Page last updated: 2024-10-25

deferiprone and Acidosis, Diabetic

deferiprone has been researched along with Acidosis, Diabetic in 1 studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Research Excerpts

ExcerptRelevanceReference
" In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice."7.73Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006)
" In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice."3.73Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ibrahim, AS1
Edwards, JE1
Fu, Y1
Spellberg, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study[NCT00419770]Phase 220 participants (Actual)Interventional2007-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Total Adverse Events

(NCT00419770)
Timeframe: 30 Days After End of Therapy

InterventionEvents (Number)
Deferasirox16
Placebo16

Other Studies

1 other study available for deferiprone and Acidosis, Diabetic

ArticleYear
Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5

    Topics: Amphotericin B; Animals; Antifungal Agents; Deferiprone; Diabetic Ketoacidosis; Humans; Iron Chelati

2006